OptiBiotix Health PLC Joint development agreement signed with Firmenich (9106R)

TIDMOPTI

RNS Number : 9106R

OptiBiotix Health PLC

11 July 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "Group")

Joint Development Agreement signed with Firmenich

OptiB i o t i x H ealth p l c (A I M : O P T I ), a li f e sc i ences bu s i n ess d e v e l o p i n g products to tac k l e o b esi t y, h i g h chole s t e r o l a n d d ia b e t e s, a nn o un ces that i t h as entered into a joint development agreement with Firmenich. The agreement allows for collaboration between both parties to develop new products containing OptiBiotix's SweetBiotix(R).

The agreement grants Firmenich rights to manufacture and sell SweetBiotix products as an ingredient or in final product solutions in return for sales based milestone and royalty payments.

Firmenich, the world's largest privately-owned fragrance and taste company, was founded in Geneva, Switzerland, in 1895. It is a leading business-to-business company specialized in the research, creation, manufacture and sale of perfumes, flavors and ingredients, and is one of the world's largest Stevia suppliers. Renowned for its world-class research and creativity, as well as its leadership in sustainability, Firmenich offers its customers superior innovation in formulation, a broad and high-quality palette of ingredients, and proprietary technologies including biotechnology, encapsulation, olfactory science and taste modulation. Firmenich products are enjoyed by 4 billion consumers a day, in more than 100 international markets and had an annual turnover of 4.3 billion Swiss Francs at end June 2021.

S tep hen O'Ha r a, CEO of O pti B i oti x, c o mmented : "We are pleased to announce the signing of a joint development agreement with Firmenich, one of the world leaders in the taste and flavour industry. The agreement brings together Firmenich's research, development, manufacturing and supply chain expertise with OptiBiotix's IP portfolio and leading expertise in the human microbiome. We believe that this agreement will help both companies collectively bring better science and better health to more people around the world ."

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 
 OptiBiotix Health plc                               www.optibiotix.com 
 Stephen O'Hara, Chief Executive                   Contact via Walbrook 
                                                                  below 
 
 
 Cairn Financial Advisers LLP (NOMAD)                Tel: [phone] 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
 Cenkos Securities plc (Broker)                      Tel: [phone] 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                                     Mob: [phone] 
 Anna Dunphy 
 
 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi ed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRGZGGNVRKGZZM

(END) Dow Jones Newswires

July 11, 2022 02:00 ET (06:00 GMT)